Pediatric Vaccines Market Synopsis:

Pediatric vaccinations are extensively in demand for preventing children from getting infectious as well as non-infectious diseases. Market Research Future (MRFR) has assessed in its latest report that the global pediatric vaccine market size is expected to expand at a double-digit CAGR of 10.6% during the projection period 2017 to 2023.

Increasing awareness about diseases and available vaccines has intensified the fueled demand for these vaccines in the past few years. A similar trend is anticipated to be witnessed in the pediatric vaccines market over the next couple of years. In addition, the advancements in the global healthcare sector are also projected to develop the market in the years to come.

Pediatric Vaccines Market Segmentation:

By type, the global pediatric vaccines market has been segmented into multivalent vaccines, monovalent vaccines, and others.

Based on technology, the pediatric vaccines market has been segmented into dendritic cells vaccines, synthetic vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, inactivated and subunit vaccines, recombinant vaccines, and others.

Based on disease indication, the global pediatric vaccines market has been segmented into polio, Haemophilus influenza type B, MMR (Measles, Mumps, and Rubella), pneumococcal disease, influenza, DTP (Diphtheria, Tetanus, Pertussis), meningococcal disease, hepatitis, combination vaccines, varicella, rotavirus, and others.

By route of administration, the pediatric vaccines market has been segmented into subcutaneous administration, intramuscular administration, oral administration, and other routes of administration

Pediatric Vaccines Market Regional Analysis:

By region, the geographical evaluation of the pediatric vaccines market spans across four major regions, viz. Americas, Europe, Asia Pacific, and the Middle East and Africa (MEA). Americas is anticipated to account for the maximum market share of the global market over the next couple of years. The increasing number of awareness campaigns organized by the healthcare service providers, organizations, and the government is expected to boost the revenue generation of the pediatric vaccines market in the region across the forecast period. The U.S. Department of Health and Human Services (HHS) is prognosticated to play a crucial role in the development of the market in the region over the next couple of years.

Europe is also projected to expand at a significant pace in the forthcoming years. The increasing investments by the governments for promoting vaccination is likely to propel the growth of the pediatric vaccines market in the years to come. Asia Pacific is also likely to witness rapid developments. The economic development of the region, in conjunction with advancements in the healthcare sector, is forecasted to catalyze proliferation of the pediatric vaccines market in the foreseeable future. The Middle East & Africa is projected to grow at a steady pace during the assessment period. Healthcare sector in the Middle East has been observing immense developments which are poised to push the market on its growth trajectory.

Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/pediatric-vaccines-market-5779

Pediatric Vaccines Market Competitive Dashboard:

The noted players of the pediatric vaccines market profiled in this MRFR report are GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), Serum Institute of India Pvt. Ltd. (India), MedImmune, LLC (U.S.), Bavarian Nordic (Denmark), Daiichi Sankyo (Japan), Protein Sciences Corporation (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), Grifols (Spain), Bharat Biotech (India), Kaketsuken (U.S.), Crucell (Netherlands), Panacea Biotec (India), Zydus Cadila (India), Nuron (U.S.), Baxter International (U.S.), S K Chemicals (South Korea), Bharat Immunologicals and Biologicals (India), Dynavax Technologies (U.S.), Lupin Pharmaceuticals, Inc. (India), Novartis AG (Switerzland), LG Life Sciences (India), Indian Immunologicals (India), Shenzhen Kangtai Biological Products (China), Bio Med (India), AstraZeneca (UK), Sinovac Biotech (China), bioCSL Inc. (U.S.), Takeda Pharmaceutical (Japan), and Valeant Pharmaceuticals (U.S.).